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Abstract
Background: Penile cancer is an uncommon malignancy with an incidence of 1 per 100,000.
Conservative and radical treatments can be disfiguring and may have an impact on sexual function,
quality of life (QOL), social interactions, self-image and self-esteem. Knowledge of how this disease
affects patients is paramount to developing a global, multi-disciplinary approach to treatment.
Methods: A Medline/PubMed literature search was conducted using the terms "sexual function
penis cancer"; "quality of life penis cancer" and "psychological effects penis cancer" from 1985 to
2008. Articles containing quantitative data on QOL, sexual function or psychological well-being
were included.
Results: 128 patients from 6 studies were included. 5 studies contained retrospective data whilst
1 study collected prospective data on erectile function. In the 6 studies 13 different quantitative
tools were used to assess psychological well-being, QOL and sexual function. The General Health
Questionnaire (GHQ) showed impaired well-being in up to 40% in 2 studies. Patients undergoing
more mutilating treatments were more likely to have impaired well-being. The Hospital Anxiety
and Depression Score (HADS) demonstrated pathological anxiety up to 31% in 2 studies. 1 study
used the Diagnostic and Statistical Manual of Mental Disorders of psychiatric illness (DSM III-R)
with 53% exhibiting mental illness, 25% avoidance behaviour and 40% impaired well-being. 12/30
suffered from post-traumatic stress disorder. The IIEF-15 was the commonest tool used to assess
sexual function. The results varied from 36% in 1 study with no sexual function to 67% in another
reporting reduced sexual satisfaction to 78% in another reporting high confidence with erections.
Conclusion: The treatment of penile cancer results in negative effects on well-being in up to 40%
with psychiatric symptoms in approximately 50%. Up to two-thirds of patients report a reduction
in sexual function. This study demonstrates that penile cancer sufferers can exhibit significant
psychological dysfunction, yet no standardised tools or interventional pathways are available.
Therefore, there is a need to identify and assess adequate tools to measure psychological and
sexual dysfunction in this group of patients.
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Cancer of the penis is a relatively uncommon malignancy
in Western countries with a reported incidence of 1 per
100,000 in Europe [1]. Social and cultural habits influ-
ence the incidence of disease which is related to exposure
to the human papilloma virus (HPV) types 16 and 18,
socio-economic factors, chronic irritation, phimosis and
smoking [2]. There are a range of treatments available for
localised early disease such as topical 5-Flurouracil ther-
apy, laser therapy, glans resurfacing and glansectomy with
reconstruction. For more advanced disease partial or total
penectomy with or without reconstruction or radiother-
apy is advocated. Surgical treatment is generally accepted
as the gold standard for high grade and high stage disease
[3,4]. In addition, patients with inguinal node disease
undergo regional lymphadenectomy which can be debili-
tating with complications such as lymphoedema, infec-
tion and wound dehiscence occurring in up to 40% of
individuals.
All treatments may be disfiguring and this may have an
impact on the patient's sexual function, quality of life
(QOL), social interactions, self-image and self-esteem.
Knowledge of how this disease affects patients will pro-
vide health professionals and organisations with the
means of identifying interventions and resources for this
group of patients.
The purpose of this review is to examine the current liter-
ature on the effects of curative penile treatment on sexual
function, quality of life and psychological well being.
Methods
An extensive Medline/PubMed literature search was con-
ducted using the terms "sexual function penis cancer";
"quality of life penis cancer" and "psychological effects
penis cancer" from 1985 to 2008. The search was under-
taken independently by two of the authors (SBM & VKS).
Abstracts were retrieved and sorted for eligibility. Those
abstracts containing quantitative data on quality of life,
sexual function or psychological well being were
included. All non-English studies, case reports, studies
reporting surgical and survival outcomes only, reviews,
editorial comments and those studies containing qualita-
tive data only were excluded from the review.
Full length articles were retrieved and reviewed to ensure
inclusion criteria were met. Any studies containing repeat
patients from the same institute were excluded. Data were
entered onto a Microsoft Excel spreadsheet for analysis.
Statistical analysis was considered in the form of weighted
and un-weighted means for those studies that contained
similar quantitative instruments and where presentation
of data and study design allowed.
Results
In total, 437 studies were found in the three searches.
Abstract review revealed that 10 studies fulfilled the inclu-
sion criteria of which 2 articles were duplicated and sub-
sequently excluded. The remainder of the abstracts
retrieved in the 3 searches did not relate directly to penile
cancer patients, focussed on only the surgical aspects of
penile cancer; the viral aetiology of penile cancer; case
reports of isolated experiences with penile cancer and
overviews/reviews of the aetiology and management of
penile cancer. Therefore, a total of 8 full journal articles
were assessed. One article contained repeat patients from
the same institution whilst another contained no quanti-
tative data for the purpose of this study. Hence 6 full arti-
cles were suitable for the purpose of this review (Table 1).
Patients
In total, there were 128 patients from 6 studies (range 14
to 36) with a mean follow-up that ranged from 11.5 to 80
months. All but 1 study contained only penile cancer
patients. The treatments received within each study
ranged from partial penectomy only, partial penectomy
and glansectomy only, laser therapy only and all treat-
ments (Table 1).
Study designs
5 studies contained retrospectively collected data whilst 1
study collected pre-treatment data on erectile function
prior to disease. The same study also asked about QOL
prior to and during disease. Therefore no single study was
entirely prospective. The control groups in each study var-
ied and included internal retrospective, internal prospec-
tive, a mixture of the previous two or external
retrospective controls (Table 2). The study by Ficarra et al
(2000) used patients who had undergone treatment for
Table 1: Studies included in systematic review
Author Bibliography Reference Year Study Published Patient Numbers Treatment Used
Ficarra [5] 2000 16 Partial penectomy
Romero [6] 2005 18 Partial penectomy
D'Ancona [7] 1997 14 Partial penectomy
Windahl [8] 2004 36 Laser Therapy
Opjordsmen [9] 1994 30 All Treatments
Gulino [10] 2007 14 Glansectomy/Partial penectomyPage 2 of 6
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[5]. This group obviously represents a separate cohort of
patients with limited parallels to those suffering with
penile cancer and therefore significantly limits the com-
parative value of the study.
In the 6 studies there were a total of 13 different quantita-
tive tools used including self made questionnaires (Table
3). These tools were administered in a variety of ways
including self administered by the patients, semi-struc-
tured interviews, general interviews and a mixture of these
methods (Table 3). In some cases similar tools were
administered in different ways in separate studies.
Statistical analysis
As no two studies contained identical measures per-
formed and presented in the same way no statistical com-
parison was possible between studies.
Psychological Well Being/Stress
The studies used a number of measures for psychological
well being. The General Health Questionnaire (GHQ)
showed impaired well being in 37.5% and 40% of
patients in the Ficarra [5] and Romero [6] studies respec-
tively whilst no patients exhibited such impairment in the
D'Ancona [7] study (Table 4). In addition, the Ficarra
study showed that patients having more mutilating treat-
ments were more likely to have impaired well being. All
three studies were retrospective and used different cut-off
values to define significant impairment.
The Hospital Anxiety and Depression Score (HADS) was
used in the D'Ancona and Romero studies and demon-
strated pathological anxiety in 0 and 31% of patients
respectively. This variation is likely to be due to differing
definition levels of significance and methods of adminis-
tration and reporting.
The Ficarra study used psychiatric interviews and assessed
patients in relation to the Diagnostic and Statistical Man-
ual of Mental Disorders of psychiatric illness (DSM III-R).
It showed that 53.3% of patients exhibited signs and
symptoms of mental illness with 2 out of 30 patients
exhibiting post-traumatic stress disorder (PTSD). Nearly





Study Design Control Group Mean Follow-up 
(months)
Ficarra [5] 2000 Retrospective Post BPH treatment 69
Romero [6] 2005 Retrospective Retrospective 23.5
D'Ancona [7] 1997 Retrospective Nil 11.5
Windahl [8] 2004 Retrospective Retrospective 36
Opjordsmen [9] 1994 Retrospective Nil 80





Table 3: Parametric tools used in each of the studies
Author Bibliography Reference Year Study Published Parametric Tools used in Study Administration of assessment 
tools





Romero [6] 2005 IIEF-I5 Interview
Single time point






Windahl [8] 2004 Self made sexual activity













Gulino [10] 2007 IIEF-15
Bigelow & Young
Self Completion
Single time pointPage 3 of 6
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exhibited impaired well being as measured by GHQ; the
latter suggesting that 12 out of 30 patients had signs of
PTSD. Interestingly the same authors also used the Euro-
pean Organisation for Research and Treatment of Cancer
quality of life questionnaire (EORTC QLQ C30) to assess
well being at a level of 3.1 (4 best to 0 worst), suggesting
mild to moderate impact on well being.
Therefore, although correlation between QOL outcome
measures is generally limited all tools used in the Ficarra
study exhibit a degree of consistency. However, the sensi-
tivity of each outcome measure can be varied depending
on the factors assessed, the manner in which they are
assessed and definitions of significance with each tool
used. In the case of the Ficarra study there is reasonable
transferable correlation and indeed sensitivity between
the GADS and GHQ-12 questionnaires. However, the sen-
sitivity of these questionnaires in relation to penile cancer
sufferers is debatable. In the D'Ancona study although
there is no stated effect of surgery on quality of life/psy-
chological well being there is again consistency between
the different outcome measures. However, the lack of
effect is a reflection of the definition of significance used
for both outcome measure tools in the study.
The Bigelow & Young questionnaire used in the Gulino
study showed that scores for feelings of unpleasantness
reduced from 30 pre-operatively to 16 following treat-
ment. In addition, scores for relationships with family/
partner improved from 4 to 16. The study scored patients
before disease (retrospectively), during disease (retrospec-
tively) and following treatment. There was no significant
difference in scores between before disease and after treat-
ment, but there was a significant improvement between
disease period and post treatment scores, suggesting a
positive impact from treatment.
Sexual Function
The International Index of Erectile Function Question-
naire (IIEF-15) was the commonest tool used for assessing
sexual function (the Romero, Windahl and Gulino stud-
ies) (Table 5). In the Windahl study, only 10 patients out
of 36 completed the IIEF-15 [8]. 6 of these were not sexu-
ally active whilst 4 scored mild to moderate erectile dys-
function. However, using the Fugl-Meyer Life Satisfaction
Check List score (LiSat-11), 50% were shown to be satis-
fied with their sex life. In the Romero study, 14 out of 18
patients (78%) had high or very high confidence in
obtaining erections, whilst 3 out of 18 (17%) had no
orgasm, 6 out of 18 (33%) had reduced sexual desire and
Table 4: Results of psychological well being/stress








Ficarra 0 n/a Performance status
GHQ
Ficarra 37.5* 9 Pathologic cut off >3
D'Ancona 0 n/a Pathologic cut off 3/4
Opjordsmen 40 n/a % ≥ 5
HADS
Ficarra 31* 2 Pathological anxiety




Opjordsmen 24.5 n/a Intrusion & avoidance ≥ 9
Bigelow & Young
Gulino 16* 30 Feelings of pleasantness
37* 18 Feelings of unpleasantness
16* 4 Relation with family/partner
22 20 Social relations
[during disease (control gp) vs post operative]
(No differences between before disease vs post op)
EORTC QLQ
Opjordsmen 3.1 n/a Overall well being
2.1 n/a Overall sexual well being
(4 best – 0 worst)
Interview DSM III-R
Opjordsmen 53.3 n/a Presence of mental symptoms
(* indicates significant result as reported in study).Page 4 of 6
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pared to pre-treatment [9]. It should be noted that
patients in this study underwent less mutilating treatment
in the form of laser therapy. The Gulino study observed
scores between before disease (retrospective) and post
treatment and showed no significant difference [10].
D'Ancona's group used the Overall Sexual Functioning
Questionnaire (OSFQ) and showed that almost 36% of
patients had no sexual function or moderately to severely
reduced sexual function [6].
Ficarra et al showed that patients had moderate sexual
function scores with a mean of 2.1 (4 = best function; 0 =
worst function) across all treatment groups, but those
patients who underwent more mutilating treatment had
lower scores (1.3 and 1.0 for partial and total penectomy
respectively) [5].
Discussion
The purpose of this systematic review was to establish the
overall effects of penile cancer and its treatment on psy-
chosexual, social and quality of life experiences.
The data suggest a mixed impact on these issues, with neg-
ative effects on well being in up to 40% and psychiatric
symptoms in approximately 50%, with signs of post-trau-
matic stress disorder in almost the same proportion. How-
ever, other studies have shown that treatment may
improve feelings of unpleasantness and poor relation-
ships. Furthermore up to two-thirds of patients exhibit
some form of negative impact on their sexual function.
Importantly, no statistical analysis was possible due to the
lack of well designed studies (level III evidence at best)
and therefore the data should be interpreted with caution.
Currently it is possible to infer that penile cancer and its
treatment can affect sexual function, psychological well
being, quality of life, and may also result in post-trau-
matic stress disorder. In cases of negative impact, these
issues are likely to provide the need for significant inter-
ventions. However the review does not provide any bear-
ing as to which types of tools can be used to identify such
problems and how such problems can be avoided or
resolved.
The limitations of this study lie in the poor quality articles
included in the analysis. The majority of studies used ret-
rospective data collection from small numbers of patients
in single units, using different measuring tools. In addi-
tion the means of delivering the study tools differed from
self administration, interview and semi-structured inter-
view. In studies that had similar measuring tools, authors
subsequently chose a different means of analysing raw
data and with varying cut-off points. These are likely to
introduce reporting bias in most of the studies. Further-
more the groups of patients studied varied in stage of dis-
ease and type of treatment administered, which is likely to
affect the amount of psychological or sexual dysfunction
experienced.
Depression and suicidal ideation is not uncommon in
cancer sufferers. Schairer et al [11] showed, from the SEER
database, that the risk of suicide amongst breast cancer
patients was 37% higher than expected when compared to
Table 5: Results of sexual function
Assessment Tool used
(Study)
Study Group (%) Control Group (%) Comment
IIEF-15
Romero 19.39* 29.56 Erectile function (14/18 with high confidence)
7.67* 9.94 Orgasm (3/18 no orgasm)
7.61* 8.89 Sexual desire (6/18 reduced post-op)
6.89* 12.67 Intercourse satisfaction (6/18 no intercourse)
6.11* 8.61 Overall satisfaction (12/18 reduced satisfaction post-op)
Windahl n/a n/a 10 had ED, 6 had no intercourse, 1 mild ED, 3 moderate ED.
Gulino 21 22 Erectile function before disease vs post-op function at 12 months
13 12 Orgasm " " " " "
8 9 Libido " " " " "
LiSat-II
Windahl 50 n/a Proportion satisfied with sex life
Self made sexual activity
Windahl 28.6 14.3 Proportion with reduced activity
Self made sexual function
Windahl 16.7 22.2 Proportion with decreased desire
ED
Windahl 16.7 8.3 Proportion decreased
(* indicates statistically significant difference as reported in study)Page 5 of 6
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the general population. A national study in Scotland
showed the relative risk of suicide to be 1.5 in cancer suf-
ferers [12]. This is especially of concern when a large pro-
portion of cancer sufferers are surviving longer. In penile
cancer, depression may exist in up to 50% of patients.
The impact of mental illness has far reaching conse-
quences including disability, co-morbidity, suicide,
reduced quality of life, lowered socioeconomic status,
dependence on welfare, increase burden of carers and an
increase in healthcare costs with the total economic bur-
den estimated at over £3.5 billion per year [13].
In the UK approximately 350 patients are diagnosed with
penile cancer each year. The majority will have 5 year dis-
ease specific survival of over 90% despite local recurrence
[14]. Hence these long term survivors will live with the
psychosocial and psychosexual effects of their treatment.
Currently, little is offered in terms of screening penile can-
cer and general cancer patients for depression or anxiety.
The NICE guidance issued in 2007 does not include any
reference to such patients [15]. Psychological dysfunction
in patients with penile cancer is likely to be common. It is
likely to have effective, economical and acceptable treat-
ment interventions, although measurement tools and
interventions in this specific group are yet to be identified
and placed in general use.
Conclusion
This study demonstrates that penile cancer sufferers can
exhibit significant psychological dysfunction, yet no
standardised tools or interventional pathways are availa-
ble. There is a need to identify adequate tools to measure
and identify psychological and sexual dysfunction in this
group of patients. Well designed multicentre studies are
warranted which will lead to the development of patient
pathways that enable the identification of patients who
require intervention.
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